Literature DB >> 10747945

Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin.

R A Pyle1, A E Schivell, H Hidaka, S M Bajjalieh.   

Abstract

Synaptic vesicle protein 2 (SV2) is a component of all synaptic vesicles that is required for normal neurotransmission. Here we report that in intact synaptic terminals SV2 is a phosphoprotein. Phosphopeptide mapping studies indicate that a major site of phosphorylation is located on the cytoplasmic amino terminus. SV2 is phosphorylated on serine and threonine but not on tyrosine residues, indicating that it is a substrate for serine/threonine kinases. Phosphopeptide mapping, in gel kinase assays, and surveys of kinase inhibitors suggest that casein kinase I is a primary SV2 kinase. The amino terminus of SV2 was previously shown to mediate its interaction with synaptotagmin, a calcium-binding protein also required for normal neurotransmission. Comparison of synaptotagmin binding with phosphorylated and unphosphorylated SV2 amino-terminal peptides reveals an increase in binding with phosphorylation. These results suggest that the affinity of SV2 for synaptotagmin is modulated by phosphorylation of SV2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747945     DOI: 10.1074/jbc.M000674200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Neurotransmitter release mechanisms in sympathetic neurons: past, present, and future perspectives.

Authors:  V M Jackson; T C Cunnane
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum.

Authors:  Maricela Dircio-Bautista; Ana Laura Colín-González; Gabriela Aguilera; Marisol Maya-López; Juana Villeda-Hernández; Sonia Galván-Arzate; Esperanza García; Isaac Túnez; Abel Santamaría
Journal:  Neurotox Res       Date:  2017-11-09       Impact factor: 3.911

3.  An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.

Authors:  Callista B Harper; Christopher Small; Elizabeth C Davenport; Darryl W Low; Karen J Smillie; Ramón Martínez-Mármol; Frédéric A Meunier; Michael A Cousin
Journal:  J Neurosci       Date:  2020-04-27       Impact factor: 6.167

Review 4.  Synaptic vesicle protein 2: A multi-faceted regulator of secretion.

Authors:  Kristine Ciruelas; Daniele Marcotulli; Sandra M Bajjalieh
Journal:  Semin Cell Dev Biol       Date:  2019-03-21       Impact factor: 7.727

5.  Mechanisms of neuromodulation as dissected using Sr2+ at motor nerve endings.

Authors:  Timothy J Searl; Eugene M Silinsky
Journal:  J Neurophysiol       Date:  2008-04-02       Impact factor: 2.714

6.  Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Authors:  V Daniels; M Wood; K Leclercq; R M Kaminski; M Gillard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  Analysis of cell type-specific expression of CK1 epsilon in various tissues of young adult BALB/c Mice and in mammary tumors of SV40 T-Ag-transgenic mice.

Authors:  Anja C Utz; Heidrun Hirner; Annette Blatz; Andreas Hillenbrand; Bernhard Schmidt; Wolfgang Deppert; Doris Henne-Bruns; Dietmar Fischer; Dietmar R Thal; Frank Leithäuser; Uwe Knippschild
Journal:  J Histochem Cytochem       Date:  2009-09-15       Impact factor: 2.479

8.  Identification of a novel Vamp1 splice variant in the cochlear nucleus.

Authors:  David R Friedland; Rebecca Eernisse; Paul Popper
Journal:  Hear Res       Date:  2008-07-09       Impact factor: 3.208

9.  A presynaptic role for PKA in synaptic tagging and memory.

Authors:  Alan Jung Park; Robbert Havekes; Jennifer Hk Choi; Vince Luczak; Ting Nie; Ted Huang; Ted Abel
Journal:  Neurobiol Learn Mem       Date:  2014-05-29       Impact factor: 2.877

10.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Authors:  Berkley A Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M Bajjalieh; Alain Matagne; Bruno Fuks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.